Grifols (GRFS) Interest Expenses (2010 - 2021)
Grifols' (GRFS) quarterly Interest Expenses came in at -$208.6 million in Q2 2018, down 372.96% YoY from $76.4 million in Q2 2017, and down 408.07% on a QoQ basis from $67.7 million in Q4 2017.
Grifols (GRFS) Interest Expenses (2010 - 2021) Analysis & Trends
Grifols (GRFS) has 9 years of Interest Expenses data on file, last reported at -$208.6 million in Q2 2018.
- Quarterly Interest Expenses fell 372.96% year-over-year to -$208.6 million in Q2 2018, while the trailing twelve-month figure through Dec 2025 was -$0.0 (changed 0.0% YoY) and the FY2025 annual result came in at $727.5 million, down 4.65% from the prior year.
- Interest Expenses declined to -$208.6 million in Q2 2018, from $67.7 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $464.4 million in Q4 2016 to a low of -$263.4 million in Q4 2015.
- A 5-year average of $56.8 million and a median of $68.3 million in 2016 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2015 — Interest Expenses soared 88556.19% — and 2018, when it slumped 372.96%.
- Tracing GRFS's Interest Expenses over 5 years: stood at $281.3 million in 2014, then plunged by 193.66% to -$263.4 million in 2015, then surged by 276.28% to $464.4 million in 2016, then slumped by 85.42% to $67.7 million in 2017, then sank by 408.07% to -$208.6 million in 2018.
- The last three Interest Expenses figures came in at -$208.6 million (Q2 2018), $67.7 million (Q4 2017), and $76.4 million (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -318.02 Mn |
| Dec 31, 2021 | -318.02 Mn |
| Dec 31, 2020 | -185.74 Mn |
| Dec 31, 2020 | -185.74 Mn |
| Dec 31, 2019 | -379.62 Mn |
| Dec 31, 2019 | -379.62 Mn |
| Jun 30, 2018 | -208.57 Mn |
| Jun 30, 2018 | -208.57 Mn |
| Dec 31, 2017 | 67.70 Mn |
| Dec 31, 2017 | 67.70 Mn |
| Jun 30, 2017 | 76.41 Mn |
| Jun 30, 2017 | 76.41 Mn |
| Dec 31, 2016 | 464.37 Mn |
| Dec 31, 2016 | 464.37 Mn |
| Sep 30, 2016 | 68.29 Mn |
| Sep 30, 2016 | 68.29 Mn |
| Jun 30, 2016 | 68.74 Mn |
| Jun 30, 2016 | 68.74 Mn |
| Mar 31, 2016 | -69.74 Mn |
| Mar 31, 2016 | -69.74 Mn |